These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 23954378)

  • 21. Evaluation of the safety and immunogenicity in rhesus monkeys of a recombinant malaria vaccine for Plasmodium vivax with a synthetic Toll-like receptor 4 agonist formulated in an emulsion.
    Lumsden JM; Pichyangkul S; Srichairatanakul U; Yongvanitchit K; Limsalakpetch A; Nurmukhambetova S; Klein J; Bertholet S; Vedvick TS; Reed SG; Sattabongkot J; Bennett JW; Polhemus ME; Ockenhouse CF; Howard RF; Yadava A
    Infect Immun; 2011 Sep; 79(9):3492-500. PubMed ID: 21690242
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Murine immune responses to a Plasmodium vivax-derived chimeric recombinant protein expressed in Brassica napus.
    Lee C; Kim HH; Choi KM; Chung KW; Choi YK; Jang MJ; Kim TS; Chung NJ; Rhie HG; Lee HS; Sohn Y; Kim H; Lee SJ; Lee HW
    Malar J; 2011 Apr; 10():106. PubMed ID: 21529346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice.
    Devi YS; Mukherjee P; Yazdani SS; Shakri AR; Mazumdar S; Pandey S; Chitnis CE; Chauhan VS
    Vaccine; 2007 Jul; 25(28):5166-74. PubMed ID: 17544179
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protective efficacy of a Plasmodium vivax circumsporozoite protein-based vaccine in Aotus nancymaae is associated with antibodies to the repeat region.
    Yadava A; Hall CE; Sullivan JS; Nace D; Williams T; Collins WE; Ockenhouse CF; Barnwell JW
    PLoS Negl Trop Dis; 2014 Oct; 8(10):e3268. PubMed ID: 25329054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity and protective efficacy of recombinant vaccine based on the receptor-binding domain of the Plasmodium vivax Duffy binding protein in Aotus monkeys.
    Arévalo-Herrera M; Castellanos A; Yazdani SS; Shakri AR; Chitnis CE; Dominik R; Herrera S
    Am J Trop Med Hyg; 2005 Nov; 73(5 Suppl):25-31. PubMed ID: 16291763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biological, immunological and functional properties of two novel multi-variant chimeric recombinant proteins of CSP antigens for vaccine development against Plasmodium vivax infection.
    Shabani SH; Zakeri S; Salmanian AH; Amani J; Mehrizi AA; Snounou G; Nosten F; Andolina C; Mourtazavi Y; Djadid ND
    Mol Immunol; 2017 Oct; 90():158-171. PubMed ID: 28800475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity of dimorphic and C-terminal fragments of Plasmodium falciparum MSP2 formulated with different adjuvants in mice.
    Balam S; Jafarshad A; Servis C; Frank G; Reed S; Pink R; Druilhe P; Spertini F; Corradin G
    Vaccine; 2016 Mar; 34(13):1566-1574. PubMed ID: 26874325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of a Plasmodium berghei transgenic parasite expressing the full-length Plasmodium vivax circumsporozoite VK247 protein for testing vaccine efficacy in a murine model.
    Mizutani M; Fukumoto S; Soubeiga AP; Soga A; Iyori M; Yoshida S
    Malar J; 2016 Apr; 15(1):251. PubMed ID: 27129682
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of immune responses elicited in mice against a recombinant malaria vaccine based on Plasmodium vivax Duffy binding protein.
    Yazdani SS; Shakri AR; Mukherjee P; Baniwal SK; Chitnis CE
    Vaccine; 2004 Sep; 22(27-28):3727-37. PubMed ID: 15315853
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccine adjuvants CpG (oligodeoxynucleotides ODNs), MPL (3-O-deacylated monophosphoryl lipid A) and naloxone-enhanced Th1 immune response to the Plasmodium vivax recombinant thrombospondin-related adhesive protein (TRAP) in mice.
    Nazeri S; Zakeri S; Mehrizi AA; Djadid ND; Snounou G; Andolina C; Nosten F
    Med Microbiol Immunol; 2018 Nov; 207(5-6):271-286. PubMed ID: 29948091
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Production of recombinant PvDBPII, receptor binding domain of Plasmodium vivax Duffy binding protein, and evaluation of immunogenicity to identify an adjuvant formulation for vaccine development.
    Bhardwaj R; Shakri AR; Hans D; Gupta P; Fernandez-Becerra C; Del Portillo HA; Pandey G; Chitnis CE
    Protein Expr Purif; 2017 Aug; 136():52-57. PubMed ID: 26578115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy.
    Bennett JW; Yadava A; Tosh D; Sattabongkot J; Komisar J; Ware LA; McCarthy WF; Cowden JJ; Regules J; Spring MD; Paolino K; Hartzell JD; Cummings JF; Richie TL; Lumsden J; Kamau E; Murphy J; Lee C; Parekh F; Birkett A; Cohen J; Ballou WR; Polhemus ME; Vanloubbeeck YF; Vekemans J; Ockenhouse CF
    PLoS Negl Trop Dis; 2016 Feb; 10(2):e0004423. PubMed ID: 26919472
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Purification, characterization, and immunogenicity of a disulfide cross-linked Plasmodium vivax vaccine candidate antigen, merozoite surface protein 1, expressed in Escherichia coli.
    Dutta S; Ware LA; Barbosa A; Ockenhouse CF; Lanar DE
    Infect Immun; 2001 Sep; 69(9):5464-70. PubMed ID: 11500418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low immunogenicity of a Plasmodium vivax circumsporozoite protein epitope bound by a protective monoclonal antibody.
    Jones TR; Yuan LF; Marwoto HA; Gordon DM; Wirtz RA; Hoffman SL
    Am J Trop Med Hyg; 1992 Dec; 47(6):837-43. PubMed ID: 1471743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A two-dose viral-vectored
    Yamamoto Y; Fabbri C; Okuhara D; Takagi R; Kawabata Y; Katayama T; Iyori M; Hasyim AA; Sakamoto A; Mizukami H; Shida H; Lopes S; Yoshida S
    Front Immunol; 2024; 15():1372584. PubMed ID: 38745665
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulation of the humoral response to repeat and non-repeat sequences of the circumsporozoite protein of Plasmodium vivax using novel adjuvant and delivery systems.
    Thomas BE; Manocha M; Haq W; Adak T; Pillai CR; Rao DN
    Ann Trop Med Parasitol; 2001 Jul; 95(5):451-72. PubMed ID: 11487368
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51.
    Herrera S; Fernández OL; Vera O; Cárdenas W; Ramírez O; Palacios R; Chen-Mok M; Corradin G; Arévalo-Herrera M
    Am J Trop Med Hyg; 2011 Feb; 84(2 Suppl):12-20. PubMed ID: 21292873
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Invasion-inhibitory antibodies elicited by immunization with Plasmodium vivax apical membrane antigen-1 expressed in Pichia pastoris yeast.
    Vicentin EC; Françoso KS; Rocha MV; Iourtov D; Dos Santos FL; Kubrusly FS; Sakauchi MA; Raw I; Nosten F; Rénia L; Rodrigues MM; Russell B; Soares IS
    Infect Immun; 2014 Mar; 82(3):1296-307. PubMed ID: 24379279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic P. vivax Vaccine.
    Alves E; Salman AM; Leoratti F; Lopez-Camacho C; Viveros-Sandoval ME; Lall A; El-Turabi A; Bachmann MF; Hill AV; Janse CJ; Khan SM; Reyes-Sandoval A
    Clin Vaccine Immunol; 2017 Apr; 24(4):. PubMed ID: 28179403
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical evaluation of a synthetic Plasmodium falciparum MAP malaria vaccine in Aotus monkeys and mice.
    Moreno CA; Rodriguez R; Oliveira GA; Ferreira V; Nussenzweig RS; Moya Castro ZR; Calvo-Calle JM; Nardin E
    Vaccine; 1999 Aug; 18(1-2):89-99. PubMed ID: 10501239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.